Fairmont The Queen Elizabeth Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

Cancer Immunotherapy: Combinations (C5)

Scientific Organizers: Chris Boshoff, Lieping Chen and Lisa Coussens


March 23—27, 2018

Fairmont The Queen Elizabeth, Montreal, Québec, Canada


Held in honor of cancer immunotherapy research pioneers Dr. Alan Korman and Dr. Nils Lonberg, thanks to generous support from an anonymous donor.

Sponsored by BioLegend, Inc., Bristol-Myers Squibb Company, Cancer Research UK, Cell Research, Incyte Corporation, MedImmune, Merck & Co., Inc., OncoMed Pharmaceuticals, Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Surface Oncology,Takeda Pharmaceutical Company Limited, TESARO, Inc. and Thermo Fisher Scientific Inc.


Abstract submission is now closed. Registered attendees may bring a poster onsite. Please contact our office at +1 800-253-0685; +1 970-262-1230 or email info@keystonesymposia.org if you are interested.
BEWARE of booking lodging through companies unaffiliated with Keystone Symposia. Click here for more details.

Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our policies.

DEADLINES:
*All deadlines end at 11:59 PM US Mountain Standard Time
Scholarship Deadline: Nov 21, 2017 [details]
Discounted Abstract Deadline: Nov 21, 2017 [details]
Abstract Deadline: Dec 19, 2017 [details]
Discounted Registration Deadline: Jan 16, 2018 [details]


Click here to view Cancellation Policy

Register Yourself Deadlines and Fees

Rates and Deadlines listed below are for the 2018-C5 "Cancer Immunotherapy: Combinations" conference only.

*All deadlines end at 11:59 PM US Mountain Standard Time

Deadline Date Cost
Discounted Abstract Deadline
More details
Before and On November 21, 2017 100.00 USD*
- 50.00 USD discount
Abstract Deadline
More details
After November 21, 2017 until February 9, 2018 100.00 USD*
* 50.00 USD of Abstract fee deducted from your registration fee when you register for this meeting
Scholarship
More details
November 21, 2017 n/a
Discounted NON-STUDENT Registration
More details
Before and On January 16, 2018 920.00 USD
(includes 200.00 discount)
Regular NON-STUDENT Registration
More details
After January 16, 2018 1120.00 USD
Discounted STUDENT Registration
More details
Before and On January 16, 2018 695.00 USD
(includes 200.00 discount)
Regular STUDENT Registration
More details
After January 16, 2018 895.00 USD

* Changes in payment type that result in a refund are subject to a processing fee.
* Currency exchange gains/losses are the responsibility of the registrant and the Keystone Symposia will accept no liability for money loss through bank charges, transfers or currency fluctuations.




Discounted Abstract Deadline: November 21, 2017

*All deadlines end at 11:59 PM US Mountain Standard Time

Abstract Submission Fee: 100.00 USD*
Submission by this date receives 50.00 USD discount.
*50.00 USD will be applied to Registration Fee when you register

Abstract Details: It is best to submit your abstract early. Abstract and registration spaces are limited and may fill prior to the abstract or discounted registration deadlines. Submitting an abstract does not constitute or guarantee registration.

Submitting your abstract early allows us to:
  • submit your abstract to organizers to be considered for a short talk
  • accept your abstract online
  • include your abstract on our website and in our secure mobile app
  • reserve your space at the meeting for a poster presentation.**
**Submitting an abstract does not constitute or guarantee registration.
(The Abstract Deadline: is December 19, 2017)

Global Health Travel Award Deadline:

*All deadlines end at 11:59 PM US Mountain Standard Time


Global Health Travel Award Details: You MUST complete your Global Health Travel Award appplication by the Global Health Travel Award Deadline and complete the other required steps (verify your contact information and submit a recommendation letter) to be considered for a travel award.


Click here to learn more about Global Health Travel Awards.

Scholarship Deadline: November 21, 2017

*All deadlines end at 11:59 PM US Mountain Standard Time


Scholarship Details: You MUST submit your abstract by the Scholarship Deadline and complete the other required steps (submit a scholarship application and submit a mentor letter) to be considered for a scholarship.

Click here to learn more about Scholarships.

Abstract Deadline: December 19, 2017

*All deadlines end at 11:59 PM US Mountain Standard Time


Abstract Submission Fee: 100.00 USD*
*50.00 USD will be applied to Registration Fee when you register

Details: It is best to submit your abstract early. Abstract and registration spaces are limited and may fill prior to the abstract or discounted registration deadline. Submitting an abstract does not constitute or guarantee registration.

Submitting your abstract by the Abstract Deadline allows us to:

  • submit your abstract to organizers to be considered for a short talk
  • include your abstract on our website and in our secure mobile app
  • reserve your space at the meeting for a poster presentation.**
**Submitting an abstract does not constitute or guarantee registration.
Abstracts submitted after the Abstract Deadline will NOT be considered for a short talk.

(Discounted Abstract Deadline: is November 21, 2017)

Discounted Registration Deadline: January 16, 2018

*All deadlines end at 11:59 PM US Mountain Standard Time


Registration Fee: 920.00 USD* (includes 200.00 USD discount)
Student Registration Fee: 695.00 USD* (must complete student verification form)

*Includes 50.00 USD of your abstract submission fee

After the Discounted Registration Deadline:


Registration Fee: 1120.00 USD*
Student Registration Fee: 895.00 USD* (must complete student verification form)

*Includes 50.00 USD of your abstract submission fee

Registration spaces are limited and may fill prior to discounted registration deadline.

Please be advised that a few meeting participants have received calls and emails from a number of different housing services - "Exhibitors Housing Services", "Global Housing", etc. THESE COMPANIES ARE NOT AFFILIATED WITH KEYSTONE SYMPOSIA and are not authorized by Keystone Symposia to contact you. These companies may tell you that the meeting is filling and seek to take your lodging reservation and obtain your credit card number. We highly recommend that you not make a reservation with these companies or any other housing service! These companies' representations to participants have been misleading. Please report to Keystone Symposia any calls or correspondence you might have received and book only through the lodging link on our website, an established travel agency, or directly with the hotel.
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


The meeting will begin on Friday, March 23 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Tuesday, March 27 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Wednesday, March 28 in order to fully experience the meeting.

FRIDAY, MARCH 23

16:00—20:00
Arrival and Registration

Agora
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Agora

SATURDAY, MARCH 24

07:30—08:30
Breakfast

Square Dorchester/Parc Mont Royal
08:30—10:00
Welcome and Keynote Session
Registered attendees can view abstracts starting on 02/23/2018

Place du Canada
* Chris H. Boshoff, Pfizer Inc., USA

* Lieping Chen, Yale University, USA

* Lisa M. Coussens, Oregon Health & Science University, USA

Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, USA
Immunologic Checkpoint Blockade: Exploring Combinations and Mechanisms

Elizabeth M. Jaffee, Johns Hopkins University, USA
Combinatorial Immunotherapy Converts Pancreatic Cancers into an Immunologic Disease

Coffee Break

10:20—11:45
Rational Immunotherapy Combinations: Preclinical Models as Predictive or Responses
Registered attendees can view abstracts starting on 02/23/2018

Place du Canada
* Judith A. Varner, University of California, San Diego, USA

Lieping Chen, Yale University, USA
Design of Combination Therapy-Based Adaptive Resistance Mechanisms in Tumor Microenvironment

Michele W. Teng, QIMR Berghofer Medical Research Institute, Australia
Dissecting the Immunological Mechanisms underlying the Efficacy of Neoadjuvant Immunotherapy

Simone Anne Minnie, QIMR Berghofer Medical Research Institute, Australia
Short Talk: Stem Cell Transplantation Establishes T Cell-Dependent Myeloma Immune-Equilibrium that Can Be Enhanced with Immunotherapy

11:45—17:00
On Own for Lunch

11:45—13:00
Poster Setup

Square Dorchester/Parc Mont Royal
13:00—22:00
Poster Viewing

Square Dorchester/Parc Mont Royal
14:30—16:30
Workshop: Novel and Sequencing Approaches

Place du Canada
* Chris H. Boshoff, Pfizer Inc., USA

Bradley N. Mills, University of Rochester, USA
Development of a New Strategy to Treat Locally Advanced Pancreatic Cancer

Adrienne Rothschilds, Massachusetts Institute of Technology, USA
Order of Administration of Combination Cytokine Therapies Can Decouple Toxicity from Efficacy in Syngeneic Mouse Tumor Models

Alvaro de Mingo Pulido, Moffitt Cancer Center, USA
TIM-3 Regulates cDC1 Function and Response to Chemotherapy in Breast Cancer

Jiemiao Hu, University of Texas MD Anderson Cancer Center, USA
Combination of Chemotherapy and Cytokine Facilitate Adoptive Transferred Effector T Cells Homing to the Core of Metastatic Tumors

Christopher D. Zahm, University of Wisconsin-Madison, USA
TLR Stimulation of Antigen-Presenting Cells Leads to IL-12 Expression that Decreases PD-1 Mediated Regulation

Hayley S. Ma, Sidney Kimmel Comprehensive Cancer Center, USA
Combination CD40 Agonist and PD-1 Antagonist Antibody Therapy Enhances Vaccine-Induced T Cell Responses in Non-Immunogenic Cancers

16:30—17:00
Coffee Available

Square Dorchester/Parc Mont Royal
17:00—19:00
Incorporating Checkpoint Inhibitors into SOC Chemo- and Radiotherapy Regimens
Registered attendees can view abstracts starting on 02/23/2018

Place du Canada
* Jane L. Grogan, Genentech, Inc., USA

Tanguy Seiwert, University of Chicago, USA
Talk Title to be Announced

Andy Minn, University of Pennsylvania, USA
Interferon-Driven Resistance Mechanisms to Immune Checkpoint Blockade Combination Therapy

Bahija Jallal, MedImmune, Inc., USA
Combination Therapy for Cancer: Beyond Checkpoint Inhibition

Hyejin Choi, Memorial Sloan Kettering Cancer Center, USA
Short Talk: Optimizing Targeted Therapy and Immune Checkpoint Blockade Therapy in Kras Mutant Lung Cancer

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Square Dorchester/Parc Mont Royal
19:30—22:00
Poster Session 1

Square Dorchester/Parc Mont Royal

SUNDAY, MARCH 25

07:30—08:30
Breakfast

Square Dorchester/Parc Mont Royal
08:30—11:30
Combining Immunotherapy with Tyrosine Kinase and Other Signaling Pathway Inhibitors
Registered attendees can view abstracts starting on 02/23/2018

Place du Canada
* Bahija Jallal, MedImmune, Inc., USA

Lisa M. Coussens, Oregon Health & Science University, USA
Dynamic Interactions between Myeloid and Lymphoid Cells Regulate Response to Therapy in Solid Tumors

Judith A. Varner, University of California, San Diego, USA
Targeting Tissue-Resident Macrophages and Their Progenitors to Suppress Cancer Progression

Coffee Break

Chris H. Boshoff, Pfizer Inc., USA
Combining Checkpoint Inhibitors with Targeted Therapies

Jane L. Grogan, Genentech, Inc., USA
Epigenetic Regulation of Tumor-Associated Myeloid Cell Activity by CBP/EP300 Bromodomain

Sabrin Mishel, University of Toronto, Canada
Short Talk: Proximal Signaling through the Innate Immune Inhibitory Receptor Signal Regulatory Protein alpha (SIRPα) in Primary Macrophages

11:30—17:00
On Own for Lunch

11:30—13:00
Poster Setup

Square Dorchester/Parc Mont Royal
13:00—22:00
Poster Viewing

Square Dorchester/Parc Mont Royal
16:30—17:00
Coffee Available

Square Dorchester/Parc Mont Royal
17:00—19:00
Sequencing vs. Combinations: Insights from Biomarker and Preclinical Studies
Registered attendees can view abstracts starting on 02/23/2018

Place du Canada
* Lisa M. Coussens, Oregon Health & Science University, USA

Sergio A. Quezada, University College London, UK
Using Preclinical Models and Clinical Samples to Inform Mechanisms and Rational Combinations

Jo A. Van Ginderachter, VIB-Vrije Universiteit Brussel, Belgium
Tumor-Associated Dendritic Cell Sub-Populations in Cancer Immunity

Bernard A. Fox, Earle A Chiles Research Institute, USA
Sequencing Checkpoint Therapies

Ralf Huss, Definiens AG, Germany
Short Talk: Multiplex Immuno-Oncology Panel for Standardized Cancer Profiling of the Immune Status Based on the Spatial and Functional Characterization in the Tumor Microenvironment

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Square Dorchester/Parc Mont Royal
19:30—22:00
Poster Session 2

Square Dorchester/Parc Mont Royal

MONDAY, MARCH 26

07:30—08:30
Breakfast

Square Dorchester/Parc Mont Royal
08:30—11:30
Immunotherapy Combinations: Preventing and Managing Resistance to Checkpoint Inhibition and T Cell Exhaustion
Registered attendees can view abstracts starting on 02/23/2018

Place du Canada
* Sergio A. Quezada, University College London, UK

Peter S. Hammerman, Novartis Institutes for BioMedical Research, USA
Adaptive Resistance to Immune Checkpoint Blockade

Andrea Schietinger, Memorial Sloan Kettering Cancer Center, USA
Molecular and Epigenetic Programs Defining Tumor-Specific T Cell Dysfunction

Coffee Break

Gregory Lawrence Beatty, University of Pennsylvania, USA
Strategies for Incorporating CD40 Agonists in Cancer Therapy

Yong-Jun Liu, Sanofi, USA
Next Generation of Immunotherapy: Targeting Anti-PD1 Resistance

Ramsay Khadeir, Barts Cancer Institute, UK
Short Talk: Pegylated Arginine Deiminase and PD-1/PD-L1 Blockade in the Treatment of ASS1-Deficient Cancers

11:30—17:00
On Own for Lunch

11:30—13:00
Poster Setup

Square Dorchester/Parc Mont Royal
13:00—22:00
Poster Viewing

Square Dorchester/Parc Mont Royal
16:30—17:00
Coffee Available

Square Dorchester/Parc Mont Royal
17:00—19:00
Overcoming T Cell Exclusion and an Immune-Privileged Microenvironment with Combination Approaches
Registered attendees can view abstracts starting on 02/23/2018

Place du Canada
* Lieping Chen, Yale University, USA

Douglas T. Fearon, Cold Spring Harbor Laboratory, USA
CXCR4 Mediates Immune Privilege in T Cell-Excluded Tumors.

Daniela F. Quail, McGill University, Canada
Macrophage and T Cell Interactions in the Brain Tumor Microenvironment

Hiroyoshi Nishikawa, National Cancer Center Japan, Japan
Control of Tumor-Associated Regulatory T Cells for Effective Cancer Immunotherapy

Casey Ager, University of Texas MD Anderson Cancer Center, USA
Short Talk: Intratumoral Delivery of a Novel STING Agonist Synergizes with Checkpoint Blockade to Regress Multi-Focal Pancreatic Cancer

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Square Dorchester/Parc Mont Royal
19:30—22:00
Poster Session 3

Square Dorchester/Parc Mont Royal

TUESDAY, MARCH 27

07:30—08:30
Breakfast

Square Dorchester/Parc Mont Royal
08:30—11:30
Vaccines, Oncolytic Viruses and Cellular Therapies: Toward Combinations
Registered attendees can view abstracts starting on 02/23/2018

Place du Canada
* Mario Sznol, Yale School of Medicine, USA

Stephen H. Thorne, University of Pittsburgh, USA
Oncolytic Viruses to Sensitize Resistant Tumors to Immunotherapy

Jeffrey Weber, New York University, USA
Clinical Efficacy and Biomarker Analyses in Patients Receiving Adjuvant Checkpoint Blockade for Resected High-Risk Stages III/IV Melanoma

Coffee Break

Olivera J. Finn, University of Pittsburgh School of Medicine, USA
Vaccines for Prevention of Non-Viral Cancers

Gerald P. Linette, University of Pennsylvania, USA
Melanoma Neoantigen Discovery and Clinical Validation

Annabelle J. Anandappa, Dana-Farber Cancer Institute, USA
Short Talk: Personal Neoantigen Vaccine for Glioblastoma Stimulates Neoepitope-Specific Intra-Tumoral T Cell Responses

11:30—17:00
On Own for Lunch

16:30—17:00
Coffee Available

Square Dorchester/Parc Mont Royal
17:00—18:45
CTLA-4: Novel Molecules and Approaches to Combinations
Registered attendees can view abstracts starting on 02/23/2018

Place du Canada
* Andrea Schietinger, Memorial Sloan Kettering Cancer Center, USA

Spencer C. Wei, University of Texas MD Anderson Cancer Center, USA
Cellular Mechanisms of Combination Checkpoint Blockade

Mario Sznol, Yale School of Medicine, USA
Lessons Learned from Anti-PD-1 and Anti-CTLA-4 Combinations

Alan J. Korman, Bristol-Myers Squibb, USA
Next-Generation Anti-CTLA-4 Antibodies

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions
Registered attendees can view abstracts starting on 02/23/2018

Place du Canada
* Chris H. Boshoff, Pfizer Inc., USA

* Lieping Chen, Yale University, USA

* Lisa M. Coussens, Oregon Health & Science University, USA

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Square Dorchester/Parc Mont Royal
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Square Dorchester/Parc Mont Royal

WEDNESDAY, MARCH 28

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

BioLegend, Inc. Bristol-Myers Squibb Company
Cancer Research UK Cell Research
Incyte Corporation MedImmune
Merck & Co., Inc. OncoMed Pharmaceuticals, Inc.
Pfizer Inc. Regeneron Pharmaceuticals, Inc.
Surface Oncology Takeda Pharmaceutical Company Limited
TESARO, Inc. Thermo Fisher Scientific Inc.

We gratefully acknowledge additional support from these exhibitors at this conference:

Immudex USA, LLC
Please stop by to meet these exhibitors during the conference.


We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1 R13 CA224868-01

Funding for this conference was made possible (in part) by 1 R13 CA224868-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


We gratefully acknowledge additional support for this conference from:

American Association for Cancer Research (AACR) American Society of Gene & Cell Therapy (ASGCT)
Avanti Polar Lipids, Inc. Bethyl Laboratories, Inc.
Charles River Eurofins Pharma Discovery Services
Infinity Pharmaceuticals, Inc.
 

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Celularity Inc.


Genentech, Inc.


Pfizer Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676